Pierre Sahakian

Head Of Regulatory Affairs at Enterome

Pierre Sahakian has extensive experience in regulatory affairs, with their most recent position being the Head of Regulatory Affairs at Enterome since July 2022. Prior to this role, they worked as a Regulatory Affairs Manager at Enterome from August 2019 to July 2022. Before joining Enterome, Pierre worked as a Freelance Consultant at Pierre Sahakian/Intermed from 2018 to 2019 and as a Regulatory Affairs Manager at ADOCIA from 2017 to 2018. Pierre also held various positions at Alizé Pharma from 2008 to 2017, where they served as the Regulatory Affairs & QA Manager and Drug Development Project Leader. Pierre's early career included roles as a Regulatory Affairs Associate and Project Leader at EUSA Pharma (OPi) from 2004 to 2007 and as a Regulatory Affairs Trainee at bioMerieux from 2003 to 2004.

Pierre Sahakian completed their education in a variety of fields. Pierre began their academic journey at Université Claude Bernard Lyon 1 from 1997 to 2004 where they earned a Doctor of Pharmacy (Pharm.D.) degree, specializing in Pharmacy. In 2003, they also pursued a Master Degree in Regulatory Affairs at IPIL while continuing their studies at Université Claude Bernard Lyon 1. Additionally, in the same year, Pierre Sahakian obtained a Master Degree in Management from emlyon business school. In 2007, they further enhanced their skills by completing a Project Leader Professional Certificate in Project Management from IFG.

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Enterome

Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect oractions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.


Headquarters

Paris, France

Employees

51-200

Links